Understanding gene-environment interactions leads to possible preventive treatment
An inhaled form of a high blood pressure medication has potential to treat certain types of anxiety as well as pain, according to a new study by the Centre for Addiction and Mental Health (CAMH).
Anxiety disorders are usually treated with different types of medications, such as antidepressants, and psychotherapy. Amiloride is a medication offering a new approach, as a short-acting nasal spray that could be used to prevent an anxiety attack.
“Inhaled amiloride may prove to have benefits for panic disorder, which is typically characterized by spells of shortness of breath and fear, when people feel anxiety levels rising,” says lead author Dr. Marco Battaglia, Associate Chief of Child and Youth Psychiatry and Clinician Scientist in the Campbell Family Mental Health Research Institute at CAMH.
The study was based on understanding the key physiological changes in brain functioning that are linked to anxiety and pain sensitivity. The researchers then tested a molecule, amiloride, which targets this functioning.
Amiloride was inhaled so that it could immediately access the brain. The study showed that it reduced the physical respiratory signs of anxiety and pain in a preclinical model of illness. This therapeutic effect didn’t occur when amiloride was administered in the body, as it didn’t cross the blood-brain barrier and did not reach the brain.
Results were published in the Journal of Psychopharmacology.
The role of early life adversity
The study is based on years of research into how a person’s early life experiences affect their genes, says Dr. Battaglia. Childhood adversity, such as loss or separation from parents, increases the risk of anxiety disorders and pain, among other health issues.
At a molecular level, these negative life experiences are linked to changes in some genes of the ASIC (acid-sensing-ion-channels) family. While the DNA itself doesn’t change, the way it functions is affected.
DNA is converted into working proteins through a process called gene expression. As a result of childhood adversity, some ASIC genes showed increased expression and epigenomic changes. (“Epigenomic” refers to changes in gene regulation that can inherited by children). Overlapping genetic changes were also seen in blood taken from twins who responded to specific tests designed to provoke panic.
These genetic changes are linked to physical symptoms. Breathing can be affected, due to over-sensitivity to higher carbon dioxide levels in the air. In such situations, a person might hyperventilate and experience growing anxiety. Preclinical and human data are strikingly similar in this regard. “As a treatment, amiloride turned out to be very effective preclinically,” says Dr. Battaglia.
The next step in his research is to test whether it eases anxiety symptoms. Dr. Battaglia is now launching a pilot clinical trial, supported through a seed grant from CAMH’s new Discovery Fund. Collaborators at the University of Utah are testing the drug’s safety.
Amiloride has been used as an oral treatment for decades for hypertension, and as an inhaled spray in a few experimental studies of cystic fibrosis, he notes. The researchers are therefore further ahead than if they had to develop and test an entirely new medication.
The Latest on: Amiloride
via Google News
The Latest on: Amiloride
- Nigerian Para powerlifter receives ban for committing an anti-doping rule violationon October 12, 2021 at 8:47 am
The International Paralympic Committee (IPC) has banned the former Paralympic champion Para powerlifter Paul Kehinde for a period of thirty (30) months for committing an anti-doping rule violation ...
- Nigerian Para-powerlifter gets 30-month ban for violating anti-doping ruleon October 12, 2021 at 1:57 am
The urine sample contained hydrochlorothiazide and its metabolite and amiloride, which are included on the world anti-doping agency (WADA) 2020 prohibited list under the class S5 diuretics and masking ...
- Nigerian Para Powerlifter Banned For 30 Monthson October 11, 2021 at 12:36 pm
The International Paralympic Committee (IPC) has banned former Paralympic champion Para powerlifter, Paul Kehinde for a period of 30 months for committing an anti-doping rule violation (ADRV).
- Nigerian para-powerlifter banned for 30 months for doping violationon October 11, 2021 at 10:47 am
The International Paralympic Committee (IPC) has banned the former Paralympic champion Para powerlifter Paul Kehin ...
- Nigerian Para powerlifter gets 30-months banon October 11, 2021 at 9:31 am
The International Paralympic Committee has issued a 30 months ban to former Paralympic champion and Nigerian Para powerlifter Paul Kehinde for committing an anti-doping rule violation.
- Monogenic Forms of Low-Renin Hypertensionon September 28, 2021 at 5:00 pm
Liddle syndrome is an autosomal dominant disorder caused by hyperactivity of the amiloride-sensitive sodium channel (ENaC) of the principal cell of the cortical collecting tubule. In 1963 ...
- Amiloride and Hydrochlorothiazideon August 30, 2021 at 4:59 pm
This information from Lexicomp ® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider.
via Bing News